摘要
目的分析研究信必可都保维持加缓解吸入治疗支气管哮喘的临床疗效及安全性。方法选择2010年3月～2011年3月在我院治疗的中、重度慢性持续期支气管哮喘患者68例,将68例患者随机分成观察组和对照组,每组各34例,观察组给予信必可都保160μg/(4.5μg.吸),1～2吸/次,2次/d规律吸入作为维持治疗,急性发作时加吸,1～3次/d作为缓解治疗;对照组给予舒利迭治疗。观察记录治疗前后两组患者的症状改善、最大呼气峰流速值(PEF)、第1秒用力呼气容积(FEV1)及不良反应等情况。结果治疗后两组患者在肺功能方面FEV1均有所提高,两组比较差异无统计学意义(P>0.05),但观察组在治疗1个月后对晨间PEF提高较对照组显著,两组比较,差异有统计学意义(P<0.05)。经治疗两组患者的哮喘症状均得到改善,但观察组症状改善更显著(P<0.05)。两组患者均无明显不良反应发生。结论吸入信必可都保可有效控制中、重度哮喘发作,改善患者肺功能和生活质量,具有良好的依从性和安全性,值得推广应用。
Objective To investigate the clinical effects and safety of Symbicort Turbuhaler in the treatment of bronchial asthma. Methods 68 patients with underwent bronchial asthma in our hospital from March 2010 to March 2011 were col- lected. 68 patients with bronchial asthma were randomly divided into observation group and control group, each group had 34 cases. The patients in observation group were treated with Symbicort Turbuhaler [160 μg/（4.5 μg suction）, 1-2 suction once, 2 times one day, the patients in control group were treated with Seretide. The clinical symptoms, lung function and adverse events of two groups were observed. Results Both groups got improvement in forced expiratory volume in 1 s （FEV1）, and there was no significant difference between the two groups. Compared with control group, observation group made rapid improvement in morning PEF, there was significant difference between the two groups （P 〈 0.05）. Asthma symptoms was improved in the two groups after treatment, improvement in observation group was earlier than that of the control group （P 〈 0.05）, there was no adverse reaction occurrence in two groups. Conclusion Symbicort Turbuhaler is safe and effective for bronchial asthma and worthy to promote in the clinic.
出处
《中国医药导报》
CAS
2012年第18期174-175,共2页
China Medical Herald
关键词
支气管哮喘
信必可都保
肺功能
临床疗效
Bronchial asthma
Symbicort Turbuhaler
Lung function
Curative effect
